New Leaf Venture Partners

The firm invests from seed through late-stage expansion, and its mandate includes PIPE transactions, buyouts, recapitalizations, and spin-offs. Portfolio disclosures span early-stage therapeutics to growth-stage digital health infrastructure. The flexibility to move between private and public-company financing is a defining feature of its strategy.

New Leaf pursues therapeutics for rare diseases, oncology, immunology, and cardiovascular conditions alongside diagnostics — including AI-driven imaging — and healthcare data infrastructure. Portfolio companies such as Cogent Biosciences and Sunbird Bio represent the therapeutic side, while Kalderos and BrightInsight address operational and compliance layers.

Ron Hunt, Vijay Lathi, and Craig Slutzkin are the only team members disclosed on the firm's website. With no additional investment professionals listed, sourcing and investment decisions likely remain concentrated among the three named partners. Media inquiries also route directly through Craig Slutzkin, suggesting a flat, low-overhead partnership.

The firm's portfolio reaches major US biotech hubs including Cambridge, South San Francisco, and Boulder, as well as international markets such as Denmark and Canada. While its own office is in New York, capital deployment follows scientific talent clusters rather than a single geography.

New Leaf's portfolio history, as self-reported, includes 54 companies taken public and 44 acquired. Several current portfolio names trade on Nasdaq, including Cogent Biosciences and Rocket Pharma, while Dice Therapeutics was acquired by Eli Lilly. The dual exit path — IPO and strategic acquisition — is central to its healthcare thesis.